Ciprofloxacin-Resistant Neisseria meningitidis, Delhi, India
Smita Singhal*, Kedar P. Purnapatre*, Vandana Kalia*, Smita Dube*, Deepti Nair†, Monorama Deb†, Pushpa Aggarwal‡, Sunil Gupta§, Dilip J. Upadhyay*, Awdhesh Kalia¶, and V. Samuel Raj*
Author affiliations: *Ranbaxy Research Laboratories, Gurgaon, India; †Vardhman Mahaveer Medical College and Safdarjung Hospital, New Delhi, India; ‡Ministry of Health and Family Welfare, New Delhi, India; §National Institute of Communicable Diseases, Delhi, India; ¶Caribbean Epidemiology Centre, Port of Spain, Trinidad and Tobago;
Figure 2. Comparison of GyrA quinolone-resistance–determining region (QRDR) for the alteration of amino acids in Neisseria meningitidis isolates. GyrA QRDR 1, ciprofloxacin-sensitive strains RRL-1, RRL-2, SFDJ 723, Ap-II 420; GyrA QRDR 2, ciprofloxacin-resistant strains SFDJ E-100, SFDJ E-79, SFDJ E-63, NICD 18, SFDJ E-95, IR-I 442; GyrA QRDR 3, ciprofloxacin-resistant strain IR-II 440. Ciprofloxacin-sensitive RRL-1 and RRL-2 were the reference strains, and the other 9 strains were from the outbreak. The shaded positions of the amino acids denote changes in GyrA QRDR of ciprofloxacin-resistant N. meningitidis in Thr-91 → Ile, Asn-103 → Asp, Ile-111 → Val, and Val-120 → Ile. The mutation of amino acid at conservative position 91 (Thr-91 → Ile) is responsible for the decreased susceptibility to fluoroquinolones, and the other 3 changes are synonymous.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.